Affiliation:
1. Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
Abstract
Savolitinib is a highly selective small molecule inhibitor of the mesenchymal epithelial transition factor (MET) tyrosine kinase, primarily developed for the treatment of non-small cell lung cancer (NSCLC) with MET mutations. It is also being investigated as a treatment for breast, head and neck, colorectal, gastric, pancreatic, and other gastrointestinal cancers. In both preclinical and clinical studies, it has demonstrated efficacy in lung, kidney, and stomach cancers. Savolitinib is an oral anti-cancer medication taken as a 600 mg dose once daily. It can be used as a monotherapy in patients with non-small cell lung cancer with MET mutations and in combination with epidermal growth factor receptor (EGFR) inhibitors for patients who have developed resistance to them. Furthermore, savolitinib has shown positive results in gastric cancer treatment, particularly in combination with docetaxel. As a result, this review aims to validate its efficacy in NSCLC and suggests its potential application in other gastrointestinal cancers, such as pancreatic cancer, based on related research in gastric and renal cancer.
Reference77 articles.
1. Comprehensive genomic characterization of squamous cell lung cancers;Hammerman;Nature,2012
2. Rocco, D., Della Gravara, L., Palazzolo, G., and Gridelli, C. (2023). The Treatment of a New Entity in Advanced Non-Small Cell Lung Cancer: MET exon 14 Skipping Mutation. Curr. Med. Chem.
3. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations;Santarpia;Transl. Lung Cancer Res.,2021
4. Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?;Kim;J. Thorac. Oncol.,2021
5. Comprehensive molecular profiling of lung adenocarcinoma;Collisson;Nature,2014